Universität zu Köln

Spiering, Wilko, Williams, Bryan, Van der Heyden, Jan, van Kleef, Monique, Lo, Rob, Versmissen, Jorie, Moelker, Adriaan, Kroon, Abraham, Reuter, Hannes, Ansel, Gary, Stone, Gregg W. and Bates, Mark (2017). Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet, 390 (10113). S. 2655 - 2662. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-547X

Full text not available from this repository.

Abstract

Background Carotid baroreflex activation lowers blood pressure and might have potential application for the treatment of resistant hypertension. We did a proof-of-principle trial with a novel endovascular baroreceptor amplification device, MobiusHD (Vascular Dynamics, Mountain View, CA, USA), in patients with resistant hypertension. Methods CALM-FIM_EUR was a prospective, first-in-human, open-label study done at six European centres. Eligible patients were adults with resistant hypertension (office systolic blood pressure >= 160 mm Hg despite taking at least three antihypertensive agents, including a diuretic). MobiusHD devices were implanted unilaterally in the internal carotid artery. The primary endpoint was the incidence of serious adverse events at 6 months. Secondary endpoints included changes in office and 24 h ambulatory blood pressure. This trial is registered with ClinicalTrials.gov, number NCT01911897. Findings Between December, 2013, and February, 2016, 30 patients were enrolled and underwent successful implantation. Mean age was 52 years (SD 12), 15 patients (50%) were men, and mean antihypertensive use was 4.4 drugs (1.4). Mean office blood pressure was 184/109 mm Hg (18/14) at baseline and was reduced by 24/12 mm Hg (13-34/6-18) at 6 months (p=0.0003 for systolic and p=0.0001 diastolic blood pressure). Mean baseline 24 h ambulatory blood pressure was 166/100 mm Hg (17/14) at baseline and was reduced by 21/12 mm Hg (14-29/7-16) at 6 months (p< 0.0001 for systolic and diastolic blood pressure). Five serious adverse events had occurred in four patients (13%) at 6 months: hypotension (n=2), worsening hypertension (n=1), intermittent claudication (n=1) and wound infection (n=1). Interpretation In patients with resistant hypertension, endovascular baroreceptor amplification with the MobiusHD device substantially lowered blood pressure with an acceptable safety profile. Randomised, double-blind, sham-controlled trials are warranted to investigate the use of this treatment further.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Spiering, Wilko UNSPECIFIED UNSPECIFIED UNSPECIFIED Williams, Bryan UNSPECIFIED UNSPECIFIED UNSPECIFIED Van der Heyden, Jan UNSPECIFIED UNSPECIFIED UNSPECIFIED van Kleef, Monique UNSPECIFIED UNSPECIFIED UNSPECIFIED Lo, Rob UNSPECIFIED UNSPECIFIED UNSPECIFIED Versmissen, Jorie UNSPECIFIED UNSPECIFIED UNSPECIFIED Moelker, Adriaan UNSPECIFIED UNSPECIFIED UNSPECIFIED Kroon, Abraham UNSPECIFIED UNSPECIFIED UNSPECIFIED Reuter, Hannes UNSPECIFIED UNSPECIFIED UNSPECIFIED Ansel, Gary UNSPECIFIED UNSPECIFIED UNSPECIFIED Stone, Gregg W. UNSPECIFIED UNSPECIFIED UNSPECIFIED Bates, Mark UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-207836
DOI:	10.1016/S0140-6736(17)32337-1
Journal or Publication Title:	Lancet
Volume:	390
Number:	10113
Page Range:	S. 2655 - 2662
Date:	2017
Publisher:	ELSEVIER SCIENCE INC
Place of Publication:	NEW YORK
ISSN:	1474-547X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language RENAL DENERVATION; BLOOD-PRESSURE; DOUBLE-BLIND; TRIAL; STIMULATION; PLACEBO; DISEASE Multiple languages Medicine, General & Internal Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/20783